|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Differences between main-duct and branch-duct intraductal papillary mucinous neoplasms of the pancreas显示文摘In the last decade,intraductal papillary mucinous neoplasms(IPMNs) have become commonly diagnosed.From a morphological standpoint,they are classified in main-duct IPMNs(MD-IPMNs) and branch-duct IPMNs(BD-IPMNs),depending on the type of involvement of the pancreatic ductal system by the neoplasm.Despite the fact that our understanding of their natural history is still incomplete,recent data indicate that MD-IPMNs and BD-IPMNs show significant differences in terms of biological behaviour with MD-IPMNs at higher risk of malignant degeneration.In the present paper,clinical and epidemiological characteristics,rates of malignancy and the natural history of MD-IPMNs and BD-IPMNs are analyzed.The profile of IPMNs involving both the main pancreatic duct and its side branches(combined-IPMNs) are also discussed.Finally,general recommendations for management based on these differences are given. | Roberto Salvia Stefano Crippa Stefano Partelli Giulia Armatura Giuseppe Malleo Marina Paini Antonio Pea Claudio Bassi | 2010 | World Journal of Gastrointestinal Surgery2010，2，10： | 14 |
| 2 | Management of ampullary neoplasms: A tailored approach between endoscopy and surgery显示文摘Ampullary neoplasms,although rare,present distinctive clinical and pathological features from other neoplastic lesions of the periampullary region.No specific guidelines about their management are available,and they are often assimilated either to biliary tract or to pancreatic carcinomas.Due to their location,they tend to become symptomatic at an earlier stage compared to pancreatic malignancies.This behaviour results in a higher resectability rate at diagnosis.From a pathological point of view they arise in a zone of transition between two different epithelia,and,according to their origin,may be divided into pancreatobiliary or intestinal type.This classification has a substantial impact on prognosis.In most cases,pancreaticoduodenectomy represents the treatment of choice when there is an overt or highly suspicious malignant behaviour.The rate of potentially curative resection is as high as 90% and in high-volume centres an acceptable rate of complications is reported.In selected situations less invasive approaches,such as ampullectomy,have been advocated,although there are some concerns mainly because of a higher recurrence rate associated with limited resections for invasive carcinomas.Importantly,these methods have the drawback of not including an appropriate lymphadenectomy,while nodal involvement has been shown to be frequently present also in apparently lowrisk carcinomas.Endoscopic ampullectomy is now the procedure of choice in case of low up to high-grade dysplasia providing a proper assessment of the T status by endoscopic ultrasound.In the present paper the evidence currently available is reviewed,with the aim of offering an updated framework for diagnosis and management of this specific type of disease. | Francesca Panzeri Stefano Crippa Paola Castelli Francesca Aleotti Alessandro Pucci Stefano Partelli Giuseppe Zamboni Massimo Falconi | 2015 | World Journal of Gastroenterology2015，21，26： | 6 |
| 3 | Extent of surgical resections for intraductal papillary mucinous neoplasms显示文摘Intraductal papillary mucinous neoplasms(IPMNs) can involve the main pancreatic duct(MD-IPMNs) or its secondary branches(BD-IPMNs) in a segmental of multifocal/diffuse fashion.Growing evidence indicates that BDIPMNs are less likely to harbour cancer and in selected cases these lesions can be managed non operatively.For surgery,clarification is required on:(1) when to resect an IPMN;(2) which type of resection should be performed;and(3) how much pancreas should be resected.In recent years parenchyma-sparing resections as well as laparoscopic procedures have being performed more frequently by pancreatic surgeons in order to decrease the rate of postoperative pancreatic insufficiency and to minimize the surgical impact of these operations.However,oncological radicality is of paramount importance,and extended resections up to total pancreatectomy may be necessary in the setting of IPMNs.In this article the type and extension of surgical resections in patients with MD-IPMNs and BD-IPMNs are analyzed,evaluating perioperative and long-term outcomes.The role of standard and parenchyma-sparing resections is discussed as well as different strategies in the case of multifocal neoplasms. | Stefano Crippa Stefano Partelli Massimo Falconi | 2010 | World Journal of Gastrointestinal Surgery2010，2，10： | 5 |
| 4 | molecular pathology of intraductal papillary mucinous neoplasms of the pancreas显示文摘Since the first description of intraductal papillary mucinous neoplasms(IPMNs)of the pancreas in the eighties,their identification has dramatically increased in the last decades,hand to hand with the improvements in diagnostic imaging and sampling techniques for the study of pancreatic diseases.However,the heterogeneity of IPMNs and their malignant potential make difficult the management of these lesions.The objective of this review is to identify the molecular characteristics of IPMNs in order to recognize potential markers for the discrimination of more aggressive IPMNs requiring surgical resection from benign IPMNs that could be observed.We briefly summarize recent research findings on the genetics and epigenetics of intraductal papillary mucinous neoplasms,identifying some genes,molecular mechanisms and cellular signaling pathways correlated to the pathogenesis of IPMNs and their progression to malignancy.The knowledge of molecular biology of IPMNs has impressively developed over the last few years.A great amount of genes functioning as oncogenes or tumor suppressor genes have been identified,in pancreatic juice or in blood or in the samples from the pancreatic resections,but further researches are required to use these informations for clinical intent,in order to better define the natural history of these diseases and to improve their management. | Marina Paini Stefano Crippa Stefano Partelli Filippo Scopelliti Domenico Tamburrino Andrea Baldoni Massimo Falconi | 2014 | World Journal of Gastroenterology2014，20，29： | 4 |
| 5 | Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology显示文摘Neuroendocrine carcinomas(NEC) of the pancreas are defined by a mitotic count > 20 mitoses/10 high power fields and/or Ki67 index > 20%, and included all the tumors previously classified as poorly differentiated endocrine carcinomas. These latter are aggressive malignancies with a high propensity for distant metastases and poor prognosis, and they can be further divided into small- and large-cell subtypes. However in the NEC category are included also neuroendocrine tumors with a well differentiated morphology but ki67 index > 20%. This category is associated with better prognosis and does not significantly respond to cisplatin-based chemotherapy, which represents the gold standard therapeutic approach for poorly differentiated NEC. In this review, the differences between well differentiated and poorly differentiated NEC are discussed considering both pathology, imaging features, treatment and prognostic implications. Diagnostic and therapeutic flowcharts are proposed. The need for a revision of current classification system is stressed being well differentiated NEC a more indolent disease compared to poorly differentiated tumors. | Stefano Crippa Stefano Partelli Giulio Belfiori Marco Palucci Francesca Muffatti Olga Adamenko Luca Cardinali Claudio Doglioni Giuseppe Zamboni Massimo Falconi | 2016 | World Journal of Gastroenterology2016，22，45： | 3 |
| 6 | Enhanced recovery pathways in pancreatic surgery: State of the art显示文摘Pancreatic surgery is being offered to an increasing number of patients every year. Although postoperative outcomes have significantly improved in the last decades, even in high-volume centers patients still experience significant postoperative morbidity and full recovery after surgery takes longer than we think. In recent years, enhanced recovery pathways incorporating a large number of evidence-based perioperative interventions have proved to be beneficial i n t e r m s o f i m p rove d p o s t o p e ra t i ve o u t c o m e s, and accelerated patient recovery in the context of gastrointestinal, genitourinary and orthopedic surgery. The role of these pathways for pancreatic surgery is still unclear as high-quality randomized controlled trials are lacking. To date, non-randomized studies have shown that care pathways for pancreaticoduodenectomy and distal pancreatectomy are safe with no difference in postoperative morbidity, leading to early discharge and no increase in hospital readmissions. Hospital costs are reduced due to better organization of care and resource utilization. However, further research is needed to clarify the effect of enhanced recovery pathways on patient recovery and post-discharge outcomes following pancreatic resection. Future studies should be prospective and follow recent recommendations for the design and reporting of enhanced recovery pathways. | Nicolò Pecorelli Sara Nobile Stefano Partelli Luca Cardinali Stefano Crippa Gianpaolo Balzano Luigi Beretta Massimo Falconi | 2016 | World Journal of Gastroenterology2016，22，28： | 2 |
| 7 | Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy显示文摘 | Giuliano Barugola Stefano Partelli Stefano Crippa Paola Capelli Mirko D’Onofrio Paolo Pederzoli Massimo Falconi | 2012 | The American Journal of Surgery2012，，2： | 2 |
| 8 | Medical treatment for gastro-entero-pancreatic neuroendocrine tumours显示文摘Gastro-entero-pancreatic neuroendocrine neoplasms(GEPNENs) represents a various family of rare tumours. Surgery is the first choice in GEP-NENs patients with localized disease whilst in the metastatic setting many other treatment options are available. Somatostatin analogues are indicated for symptoms control in functioning tumours. Furthermore they may be effective to inhibit tumour progression. GEP-NENs pathogenesis has been extensively studied in the last years therefore several driver mutations pathway genes have been identified as crucial factors in their tumourigenesis. GEP-NENs can over-express vascular endothelial growth factor(VEGF), basic-fibroblastic growth factor, transforming growth factor(TGF-α and-β), platelet derived growth factor(PDGF), insulin-like growth factor-1(IGF-1) and their receptors PDGF receptor, IGF-1 receptor, epidermal growth factor receptor, VEGF receptor, and c-kit(stem cell factor receptor) that can be considered as potential targets. The availability of new targeted agents, such as everolimus and sunitinib that are effective in advanced and metastatic pancreatic neuroendocrine tumours, has provided new treatment opportunities. Many trials combing new drugs are ongoing. | Rossana Berardi Francesca Morgese Mariangela Torniai Agnese Savini Stefano Partelli Silvia Rinaldi Miriam Caramanti Consuelo Ferrini Massimo Falconi Stefano Cascinu | 2016 | World Journal of Gastrointestinal Oncology2016，8，4： | 2 |
| 9 | Mucin-Producing Neoplasms of the Pancreas: An Analysis of Distinguishing Clinical and Epidemiologic Characteristics显示文摘 | Stefano Crippa Carlos Fernández–del Castillo Roberto Salvia Dianne Finkelstein Claudio Bassi Ismael Domínguez Alona Muzikansky Sarah P. Thayer Massimo Falconi Mari Mino–Kenudson Paola Capelli Gregory Y. Lauwers Stefano Partelli Paolo Pederzoli Andrew L. W | 2010 | Clinical Gastroenterology and Hepatology2010，，2： | 2 |
| 10 | Current status of robotic distal pancreatectomy: A systematic review显示文摘 | Roberto Cirocchi Stefano Partelli Andrea Coratti Jacopo Desiderio Amilcare Parisi Massimo Falconi | 2013 | Surgical Oncology2013，，： | 2 |
| 11 | Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor显示文摘 | Rossella Bettini Stefano Partelli Letizia Boninsegna Paola Capelli Stefano Crippa Paolo Pederzoli Aldo Scarpa Massimo Falconi | 2011 | Surgery2011，，： | 2 |
| 12 | Resectable Pancreatic Cancer: Who Really Benefits From Resection?显示文摘 | Giuliano Barugola MD Stefano Partelli MD Stefano Marcucci MD Nora Sartori MD Paola Capelli MD Claudio Bassi MD Paolo Pederzoli MD Massimo Falconi MD | 2009 | Annals of Surgical Oncology2009，，12： | 2 |
| 13 | A systematic review on robotic pancreaticoduodenectomy显示文摘 | Cirocchi R Partelli S Trastulli S | 2013 | Surg Oncol2013，22，4： | 1 |
| 14 | Portal vein embolization and ligation for extended hepatectomy显示文摘 | Vyas S Markar S Partelli S | 2014 | Indian J Surg Oncol2014，5，1： | 1 |
| 15 | Current status of robotic distal pancreatectomy:a systematic review显示文摘 | Cirocchi R Partelli S Coratti A | 2013 | Surg Oncol2013，22，3： | 1 |
| 16 | Middle Pancreatectomy: Indications, Short- and Long-term Operative Outcomes显示文摘 | Stefano Crippa Claudio Bassi Andrew L. Warshaw Massimo Falconi Stefano Partelli Sarah P. Thayer Paolo Pederzoli Carlos Fernández-del Castillo | 2007 | Annals of Surgery2007，，1： | 1 |
| 17 | Partial Pancreaticoduodenectomy Can Provide Cure for Duodenal Gastrinoma Associated With Multiple Endocrine Neoplasia Type 1显示文摘 | Caroline L. Lopez Massimo Falconi Jens Waldmann Letizia Boninsegna Volker Fendrich Peter K. Goretzki Peter Langer Peter H. Kann Stefano Partelli Detlef K. Bartsch | 2013 | Annals of Surgery2013，，2： | 1 |
| 18 | Parenchyma-sparing resections for pancreatic neoplasms 显示文摘 | Crippa S Boninsegna L Partelli S | 2010 | J Hepatobiliary Pancreat Sci2010，17，6： | 1 |
| 19 | Resectable Pancreatic Cancer: Who Really Benefits From Resection?显示文摘 | Giuliano Barugola Stefano Partelli Stefano Marcucci Nora Sartori Paola Capelli Claudio Bassi Paolo Pederzoli Massimo Falconi | 2009 | Annals of Surgical Oncology2009，，： | 1 |
| 20 | Pancreatic Surgery显示文摘 | Maurizi A Partelli S Falconi M | 2015 | Front HormRes2015，，44： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员